Evaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21106-e21106
Author(s):  
Vamsidhar Velcheti ◽  
Huan Cheng ◽  
Xiaopan Yao ◽  
Yanhong Deng ◽  
Scott N. Gettinger ◽  
...  
Keyword(s):  
Embryonic Stem ◽  
University Hospital ◽  
Rank Test ◽  
Molecular Characteristics ◽  
Test Results ◽  
New Haven ◽  
Sox2 Expression ◽  
Kaplan Meier ◽  
Quantitative Immunofluorescence ◽  
Independent Cohort

e21106 Background: SOX2 is an embryonic stem cell transcription factor that plays a crucial role in differentiation and maintaining pluripotency. We examine the pattern of SOX2 expression and assess correlation with CP features in NSCLC. Methods: Using the AQUA method of automated quantitative immunofluorescence we measured SOX2 expression in two cohorts (in a tissue microarray format), from Yale New Haven Hospital (YTMA 79) and an independent cohort from Patras University Hospital in Greece (YTMA 140) (196 and 342 cases, respectively). YTMA 140 had high percentage of Squamous cell carcinoma (SCC) (48.8%) as opposed to 17.9% in YTMA 79. There were more stage III & IV pts in YTMA 140 (41.3%) compared to YTMA79 (30.6%). 88% of pts in the YTMA 140 were male compared to 52.5% in YTMA79. Survival analysis was done using Kaplan-Meier analysis with log-rank test. The associations between SOX2 expression level and CP features were evaluated by using non-parametric Kruskal-Wallis test. Results: In both cohorts, we found significantly higher SOX2 expression in SCC compared to adenocarcinoma. There was no correlation with gender or stage. Using the threshold of specific signal detection as the cut point, we divided the cohorts into expressers and non-expressers. YTMA 140 cohort which is enriched in SCC showed that 28/161(17.3%) pts with SCC were SOX2 non-expressers. Pts who were SOX2 non-expressers had a worse median overall survival (15 months) compared to pts who were SOX2 expressers (23.5 months) (p=0.015). Conclusions: Our data reveals that pts who have SCC have significantly higher expression of SOX2 and higher SOX2 expression correlates with better outcome. Further studies to define the molecular characteristics of SCC may elucidate more effective markers and effective classification for NSCLC.

scholarly journals Comparative efficacy of tocilizumab and baricitinib in COVID-19 treatment: a retrospective cohort study

2021 ◽  
Author(s):  
Yuichi Kojima ◽  
Sho Nakakubo ◽  
Keisuke Kamada ◽  
Yu Yamashita ◽  
Nozomu Takei ◽  
...  
Keyword(s):  
Chronic Renal Disease ◽  
Secondary Infection ◽  
University Hospital ◽  
Rank Test ◽  
Logistic Regression Models ◽  
Respiratory Status ◽  
Kaplan Meier ◽  
Single Center Study ◽  
Significant Difference ◽  
All Cause Mortality

SummaryBackgroundAlthough biological agents, tocilizumab and baricitinib, have been shown to improve the outcomes of patients with COVID-19, a comparative evaluation has not been performed.MethodsA retrospective, single-center study was conducted using the data of patients with COVID-19 admitted to the Hokkaido University hospital between April 2020 and September 2021, who were treated with tocilizumab or baricitinib. The clinical characteristics of patients who received each drug were compared. Univariate and multivariate logistic regression models were performed against the outcomes of all-cause mortality and the improvement in respiratory status. The development of secondary infection events was analyzed using the Kaplan–Meier analysis and the log-rank test.ResultsThe use of tocilizumab or baricitinib was not associated with all-cause mortality and the improvement in respiratory status within 28 days of drug administration. Age, chronic renal disease, and comorbid respiratory disease were independent prognostic factors for all-cause mortality, while anti-viral drug use and severity of COVID-19 at baseline were associated with the improvement in respiratory status. There was no significant difference in the infection-free survival between patients treated with tocilizumab and those with baricitinib.ConclusionThere were no differences in efficacy and safety between tocilizumab and baricitinib for the treatment of COVID-19.

scholarly journals The prognostic role of tissue TLR2 and TLR4 in colorectal cancer

2020 ◽  
Vol 477 (5) ◽  
pp. 705-715
Author(s):  
Ines Beilmann-Lehtonen ◽  
Camilla Böckelman ◽  
Harri Mustonen ◽  
Selja Koskensalo ◽  
Jaana Hagström ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Distant Metastases ◽  
University Hospital ◽  
Rank Test ◽  
Pathogen Invasion ◽  
Kaplan Meier ◽  
Node Positive Disease ◽  
Colorectal Cancer Patients ◽  
Dukes C

Abstract Colorectal cancer (CRC), the second most common cancer globally, resulted in 881,000 deaths in 2018. Toll-like receptors (TLRs) are crucial to detecting pathogen invasion and inducing the host’s immune response. This study aimed to explore the prognostic value of TLR2 and TLR4 tumor expressions in colorectal cancer patients. We studied the immunohistochemical expressions of TLR2 and TLR4 using tissue microarray specimens from 825 patients undergoing surgery in the Department of Surgery, Helsinki University Hospital, between 1982 and 2002. We assessed the relationships between TLR2 and TLR4 expressions and clinicopathological variables and patient survival. We generated survival curves using the Kaplan-Meier method, determining significance with the log-rank test. Among patients with lymph node–positive disease and no distant metastases (Dukes C), a strong TLR2 immunoactivity associated with a better prognosis (p < 0.001). Among patients with local Dukes B disease, a strong TLR4 immunoactivity associated with a worse disease-specific survival (DSS; p = 0.017). In the multivariate survival analysis, moderate TLR4 immunoactivity compared with strong TLR4 immunoactivity (hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.49–0.89, p = 0.007) served as an independent prognostic factor. In the multivariate analysis for the Dukes subgroups, moderate TLR2 immunoactivity (HR 2.63, 95% CI 1.56–4.44, p < 0.001) compared with strong TLR2 immunoactivity served as an independent negative prognostic factor in the Dukes C subgroup. TLR2 and TLR4 might be new prognostic factors to indicate which CRC patients require adjuvant therapy and which could spare from an unnecessary follow-up, but further investigations are needed.

Effect of body mass index (BMI) on outcomes after surgical resection and adjuvant therapy for pancreatic cancer patients.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 185-185
Author(s):  
M. R. Khawaja ◽  
N. Zyromski ◽  
M. Yu ◽  
H. R. Cardenes ◽  
C. M. Schmidt ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Surgical Resection ◽  
Survival Rates ◽  
Disease Free Survival ◽  
University Hospital ◽  
Rank Test ◽  
Kaplan Meier ◽  
Significant Difference

185 Background: Obesity is one of the factors commonly associated with pancreatic cancer risk, but its prognostic role for survival is debatable. This study aimed to determine the role of BMI in treatment outcomes of pancreatic cancer patients (pts) undergoing surgical resection followed by adjuvant therapy. Methods: We retrospectively reviewed 165 consecutive pts with pancreatic cancer undergoing pancreaticoduodenectomy at Indiana University Hospital between 2004 and 2008. Fifty-three pts who received adjuvant treatment [gemcitabine alone (C-group): n=19; gemcitabine + radiotherapy (CRT-group): n=34] at our institution were included in the analysis. The Kaplan-Meier method was used to estimate the disease-free survival (DFS) and overall survival (OS); log-rank test was used to compare these outcomes between BMI groups (normal 18.5-24.99 kg/m2 vs. overweight/obese ≥ 25 kg/m2). Results: The sample comprised 53 pts (28 males; median age 62 yrs) with a median follow-up of 18.6 months (mos). Thirty pts (56.6%) had their BMIs recorded before the date of surgery, and 23 pts prior to starting adjuvant therapy. Two (3.8%) pts were underweight, 21 (39.6%) had a normal BMI and 30 (56.6%) were overweight/obese. There was no statistically significant difference in the median DFS of obese/overweight and normal BMI pts irrespective of adjuvant therapy (C or CRT) (14.47 vs. 11.80 mos; p= 0.111). Obese/overweight pts had a better median OS [25.2 vs. 14.6 mos; p=0.045 overall (25.7 vs. 16.9 mos; p= 0.143 for the CRT-group and 17.3 vs. 13.4 mos; p= 0.050 for the C-group)], 1-year survival [96.7% vs. 61.9%; p < 0.0001 overall (95% vs. 64.3%; p= 0.001 for the CRT-group, and 90% vs. 57.1%; p=0.016 with C)], and 2-year survival [52.6% vs. 25.4%; p < 0.0001 overall (60.0% vs. 30.0%; p=0.0001 for the CRT-group and 37.5% vs. 14.3%; p=0.0002 for the C-group)] than patients with normal BMI. Conclusions: In our experience, overweight/obese pts undergoing surgery followed by adjuvant therapy have better survival rates than patients with normal BMI. [Table: see text] No significant financial relationships to disclose.

Oral (O) versus intravenous (IV) etoposide and platinum in the treatment of extensive-stage small cell lung cancer (SCLC).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 7597-7597 ◽  
Author(s):  
Scott Alan Dorroh ◽  
Eric R Siegel ◽  
Rangaswamy Govindarajan
Keyword(s):  
Poor Performance ◽  
Rank Test ◽  
Test Results ◽  
Extensive Disease ◽  
Tumor Registry ◽  
Log Rank Test ◽  
Kaplan Meier ◽  
Extensive Stage ◽  
Pharmacy Data

7597 Background: Platinum and etoposide chemotherapy is the treatment for patients with SCLC. O etoposide is substituted for IV by many clinicians at twice the dose for bioavailability but the outcome of these subjects has not been studied. To compare the efficacy of O vs. IV etoposide in extensive stage SCLC, a retrospective analysis of subjects treated in the VISN 16 network of 10VA hospitals was undertaken. Methods: Subjects with SCLC diagnosed between 10/1/1996 and 9/30/2010 were identified from the VISN-16 tumor registry. Study was limited to extensive disease by excluding those treated with radiation therapy. Chemotherapy details were obtained from the pharmacy data in the VISN 16 database. Overall survival (OS) was computed as the time in months from the first etoposide issue date to the date of death or last contact. Kaplan-Meier methods were used to compute median OS, and etoposide groups were compared via log-rank test. Results: 300 subjects were eligible for analysis, with median age 67 yrs (range 45-84). 295 deaths were observed during 2,419 total months of follow-up. The median OS of all subjects was 6.3 months (interquartile range (IQR) 2.0-11 months). In addition to platinum, 153 subjects received only O etoposide, 147 received some form of IV etoposide. The median duration (IQR) of therapy for all subjects was 29 (1-110) days; 23 days for those who received any IV etoposide and 43 days for those who received only oral etoposide. The median OS was 7.6 months for those who received only O etoposide vs. 5.4 months for any IV etoposide (P<0.0001). In the latter group, those receiving purely IV etoposide had only 1.5 months’ median OS vs. 8.8 months for those receiving both O and IV etoposide (P<0.0001). Conclusions: Survival of subjects with SCLC treated with O etoposide is comparable to those who received a combination of O and IV therapy. Poor OS for those with only IV therapy may be due to selection bias of poor-performance subjects. [Table: see text]

Calcium channel blockers use and overall survival in pancreatic cancer patients receiving gemcitabine.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15756-e15756 ◽  
Author(s):  
Leszek Kraj ◽  
Andrzej Śliwczyński ◽  
Joanna Krawczyk-Lipiec ◽  
Krzysztof Woźniak ◽  
Anna Waszczuk-Gajda ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Calcium Channel ◽  
Calcium Channel Blockers ◽  
Rank Test ◽  
Channel Blockers ◽  
Test Results ◽  
Log Rank Test ◽  
Kaplan Meier ◽  
Significant Difference

e15756 Background: Preclinical studies have shown that calcium channel blockers (CCB) may potentiate anticancer effect of chemotherapy via intra-cellular drug accumulation. Gemcitabine-based chemotherapy is commonly used in pancreatic cancer (PC) patients. The aim of this study was to determine whether CCB may affect overall survival (OS) in PC patients receiving gemcitabine-based chemotherapy. Methods: The retrospective cohort of PC patients treated with gemcitabine between 2007 and 2016 was identified in the Polish National Health Fund databases. Electronic records of prescriptions were searched to identify in this cohort patients receiving CCB (amlodipine, nitrendipine, felodipine, lacidipine). The primary endpoint was OS and it was determined by Kaplan-Meier methods and compared by the log-rank test. Results: In total 4628 PC patients treated with gemcitabine (median OS 7.7 months; 95% CI: 7.4-7.9) were identified. Among these 380 patients were prescribed any CCB. There was a significant difference (p < 0.001) in median OS between patients prescribed CCB (n = 380; OS 9.3 months; 95% CI: 7.8-11.0) and those who did not (n = 4214; OS 7.6 months; 95% CI: 7.3-7.8) with hazard ratio for death 0.70 (95% CI: 0.62-0.79). Notably, the survival curves tended to flatten in CCB group, with 24% of patients alive at 2 years (95% CI: 20-29%) and 15% alive at 5 years (95% CI: 11-19%), compared with 11% (95% CI: 10-12%) and 4% (95% CI: 4-5%) in controls respectively. Conclusions: The use of CCB in PC patients receiving gemcitabine-based chemotherapy was associated with improved OS. Further validation is needed to evaluate effectiveness of CCB-gemcitabine combinations in the management of PC.

Clinical and molecular characteristics of TSC1/2 mutant lung cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21647-e21647
Author(s):  
Yanye Wang ◽  
Song Xu ◽  
Shikang Zhao ◽  
Shuai Zhu ◽  
Xiongfei Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Smoking History ◽  
Rank Test ◽  
Molecular Characteristics ◽  
Fisher Exact Test ◽  
Continuous Variables ◽  
Cancer Dataset ◽  
Kaplan Meier ◽  
Oncogenic Gene ◽  
Gene Alterations

e21647 Background: Tumor suppressor genes TSC1 and TSC2 inhibit cell growth through inactivation the function of mTORC1. Previous studies have demonstrated that loss of function mutation of either TSC1 or TSC2 gene result in formation of neoplasm in multiple tissues. However, the clinical significance of TSC1 and TSC2 in non-small-cell lung cancer (NSCLC) remains unknown. This study aimed to investigate the clinical and molecular characteristics of TSC1 and TSC2 mutation in NSCLC patients. Methods: We retrieved the clinical and genomic information of 1144 NSCLC from the Pan-Lung cancer dataset through the cBioportal ( www.cbioportal.org) . The cohorts of TSC1 and TSC2 mutant patients were identified. We compared baseline characteristics of patients with the Fisher exact test for categorical data and the Mann-Whitney U test for continuous variables. Overall survival (OS) was estimated with Kaplan-Meier curves, and differences were compared with the log-rank test. Results: Among 1144 patients, 27(2.36%) of them had TSC1 mutation and 40 (3.50%) had TSC2 mutation. Most patients with TSC1 and TSC2 mutations coexisted with other oncogenic gene alterations. TP53 was the most frequent concurrent gene (n = 53), followed with ERBB family genes (n = 24) and KRAS (n = 15). Compared to squamous cell carcinoma, TSC1/2 mutation was slightly more common in adenocarcinoma (53.7% vs 46.3%). 61.2% TSC1/2 mutant patients were male and 88.1% patients had former/current smoking history. Kaplan–Meier analysis showed that the patients harboring TSC1 mutation had a median OS of 14.1 months, whereas patients with TSC2 mutation had a median OS 110.6 months. However, there was not a statistically difference (P = 0.201). Conclusions: TSC1/2 mutation may define a unique population of NSCLC, which often coexists with other oncogenic gene alterations such as TP53 mutation. The function of TSC1/2 mutation and the value of TSC1/2 as therapeutic target in NSCLC are under investigation.

scholarly journals Prognosis of patients with acute exacerbation of combined pulmonary fibrosis and emphysema: A retrospective single-center study

2020 ◽  
Author(s):  
Yuichi Ikuyama ◽  
Atsuhito Ushiki ◽  
Makoto Kosaka ◽  
jumpei Akahane ◽  
Yuichi Mukai ◽  
...  
Keyword(s):  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
White Blood Cells ◽  
University Hospital ◽  
Rank Test ◽  
Clinical Prognosis ◽  
Kaplan Meier ◽  
Median Serum ◽  
Respiratory Management ◽  
Before And After

Abstract Background: Previous analyses of combined pulmonary fibrosis and emphysema (CPFE) cohorts have provided conflicting data on the survival of patients with CPFE. Therefore, the aim of this study was to investigate the clinical prognosis of acute exacerbation (AE) of CPFE. Methods : We retrospectively reviewed the medical records of patients who had been treated at Shinshu University Hospital (Matsumoto, Japan) between 2003 and 2017. We identified 21 patients with AE of CPFE and 41 patients with AE of idiopathic pulmonary fibrosis (IPF) and estimated their prognoses using the Kaplan–Meier method. Results : Treatment content and respiratory management were not significantly different between the two groups before and after exacerbation. At the time of AE, the median serum Krebs von den Lungen-6 level was significantly lower in the CPFE group (Krebs von den Lungen-6: 966 U/µL; white blood cell count: 8810 /µL) than that in the IPF group (Krebs von den Lungen-6: 2130 U/µL, p < 0.001; white blood cells: 10809/µL, p = 0.0096). The baseline Gender-Age-Physiology score was not significantly different between the two groups (CPFE, 4.5 points; IPF, 4.7 points; p = 0.58). Kaplan–Meier curves revealed that the survival time after AE for patients with CPFE was longer than that for patients with IPF ( p < 0.001, log-rank test). Conclusions : Survival prognoses after AE were significantly better for patients with CPFE than that for patients with IPF. Our findings may improve the medical treatment and respiratory management of patients with AE-CPFE.

scholarly journals Impact of Recurrence Pattern in Patients Undergoing a Second Surgery for Recurrent Glioblastoma

2021 ◽  
Author(s):  
Francesco Pasqualetti ◽  
Nicola Montemurro ◽  
Isacco Desideri ◽  
Mauro Loi ◽  
Noemi Giannini ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Recurrent Glioblastoma ◽  
University Hospital ◽  
Rank Test ◽  
Recurrence Pattern ◽  
Kaplan Meier ◽  
Second Surgery ◽  
Non Local ◽  
The Impact ◽  
Recurrent Gbm

Abstract Background. The impact of different patterns of glioblastoma (GBM) recurrence has not yet been fully established in patients suitable for a second surgery. Through the present observational study carried out at Pisa University Hospital, we aimed to examine the impact of different patterns of GBM failure on patients’ survival and second surgery outcomes.Methods. Overall survival was assessed according to clinical characteristics, including pattern of recurrence, in a prospective cohort of recurrent GBM patients. Survival curves were calculated using the Kaplan-Meier method and the log-rank test was applied to evaluate the differences between curves.Results. Contact with ventricles, a second surgery and meningeal spread had a statistically impact on patient survival after the diagnosis of GBM recurrence (P=0.032, P=0.019 and P<0.01, respectively). Patients with local recurrence had better survival than patients with non-local ones, 24.1 versus 18.2 months, respectively (P=0.015, HR=1.856 (1.130 -3.050). Considering the cohort as a whole, the second surgery conferred an advantage in recurrent survival respect to non-operated patients. However, this advantage was more evident in patients with local recurrence (P=0.002 with HR 0.212 (95% CI 0.081-0.552) and P=0.029 with HR=0.522 (95% CI 0.291-0.936), respectively). Conclusions. The local recurrence pattern could be a promising field of interest for patients with recurrent GBM suitable for a second surgery.

scholarly journals Survival and Prognostic Factors for Outcome after Radiotherapy for T2 Glottic Carcinoma

Cancers ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 1319 ◽  
Author(s):  
Hendriksma ◽  
Ruler ◽  
Verbist ◽  
Jong ◽  
Langeveld ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Anterior Commissure ◽  
Rank Test ◽  
Consecutive Series ◽  
Glottic Carcinoma ◽  
Test Results ◽  
Log Rank Test ◽  
Kaplan Meier ◽  
Patients At Risk ◽  
The Impact

Background: Local recurrence after radiotherapy for T2 glottic carcinoma remains an issue and identifying patients at risk for relapse is, therefore, important. This study aimed to assess the oncological outcomes and prognostic factors in a consecutive series of patients treated with radiotherapy for T2N0 glottic carcinoma. Methods: Patients with T2N0 glottic carcinoma treated with radiotherapy were included in this retrospective study. Five- and ten-year local control (LC), overall survival (OS), disease-specific survival (DSS), and laryngeal preservation (LP) rates were calculated with the Kaplan–Meier method. The impact of prognostic variables was evaluated with the log-rank test. Results: Ninety-four patients were included for analysis. LC, OS, DSS, and LP rates were 70.5, 63.7, 86.0, and 74.7%, respectively at five years and 65.8, 41.0, 75.6, and 72.4% at 10 years. In total, 46 scans were included in the analyses. Vertical involvement of the anterior commissure on imaging showed a significant impact on LC. Conclusions: In accordance with previously described surgical risk factors, we identified vertical involvement of the anterior commissure on imaging as a prognostic factor for radiation failure.

Endoscopic thermal ablation therapies for hepatocellular carcinoma; multi-center study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4147-4147
Author(s):  
H. Sakaguchi ◽  
S. Seki ◽  
S. Iwai ◽  
H. Kadoya ◽  
K. Ido ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Local Anesthesia ◽  
Scoring System ◽  
Thermal Ablation ◽  
Survival Rates ◽  
Rank Test ◽  
Test Results ◽  
Kaplan Meier ◽  
Multi Center Study ◽  
Center Study

4147 Background: Differences of efficacy between radiofrequency ablation (RFA) and microwave coagulation (MWC) for hepatocellular carcinoma (HCC) is still unknown. So we performed multi-center study to assess factors contributing to survival among patients treated by endoscopic thermal ablation for single HCC. Methods: 396 patients in six institutions with single HCC who were firstly treated by endoscopic thermal ablation were enrolled in this study and assessed retrospectively. Among 396 patients, 347 were treated under general anesthesia and 49 were treated local anesthesia. 144 were treated by MWC and 252 were treated by RFA. 383 were ablated laparoscopically and 13 were done thoracoscopically. 230 HCCs were located superficial position of liver and 166 were deep position. Classification with Child-Turcotte-Pugh score, the Japan Integrated Staging score, and the Cancer of the Italian Program scoring system were performed. All patients were analyzed survival rates by Kaplan-Meier method and differences among groups were compared by the log-rank test. Results: Five year survival rates of all 396 patients were 63% and ten year survival rates were 42%. Differences between general and local anesthesia were not significant (p = 0.28). Differences between MWC and RFA were not significant (p = 0.77). Location of HCCs were not significant (p = 0.89). Differences among groups classified by Child-Turcotte-Pugh score were significant (p = 0.017). Classification by the Japan Integrated Staging score was not significant (p = 0.24). However, classification by the Cancer of the Italian Program scoring system were significant (p = 0.001). Conclusions: Endoscopic thermal ablation therapies for HCC was effective. Differences of efficacy between RFA and MWC were not found. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document